Logotipo do repositório
 

Publicação:
Daptomycin: Physicochemical, Analytical, and Pharmacological Properties

dc.contributor.authorTotoli, Eliane Gandolpho [UNESP]
dc.contributor.authorGarg, Sanjay
dc.contributor.authorNunes Salgado, Herida Regina [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniv S Australia
dc.date.accessioned2018-11-27T05:34:21Z
dc.date.available2018-11-27T05:34:21Z
dc.date.issued2015-12-01
dc.description.abstractDaptomycin is the first approved member of a new class of antimicrobials, the cyclic lipopeptides, and presents selective action against gram-positive bacteria, including methicillin- and vancomycin-resistant strains. Considering that resistance to daptomycin is rare, the drug has become very important for current clinical practice. This review covers daptomycin's physicochemical characteristics, antibacterial spectrum, mechanism of action, pharmacokinetics, clinical applications, side effects, drug interactions, and the analytical methods used to measure daptomycin in pharmaceutical products and biologic samples. Special attention has been given to therapeutic drug monitoring reports, as studies have shown its highly variable pharmacokinetics in specific circumstances, such as in patients suffering from critical illness, morbid obesity, severe sepsis, and kidney injury. For the same reason, methods described for therapeutic drug monitoring of daptomycin in the special patient population have been reviewed. In addition, the review presents a discussion of environmentally friendly analytical methods for daptomycin, which are necessary to reduce the impact of our activities on the environment. However, it was observed that there is a gap in the literature in this regard and further research involving the development of green methodologies for the analysis of daptomycin is necessary. The review will be useful to the clinical community in assisting with the responsible use of daptomycin, which is critical to prevent the emergence of resistant strains.en
dc.description.affiliationUniv Estadual Paulista, Sch Pharmaceut Sci, BR-14801902 Araraquara, Brazil
dc.description.affiliationUniv S Australia, Ctr Pharmaceut Innovat & Dev, Adelaide, SA 5001, Australia
dc.description.affiliationUnespUniv Estadual Paulista, Sch Pharmaceut Sci, BR-14801902 Araraquara, Brazil
dc.description.sponsorshipPACD-FCFAr-UNESP (Araraquara, Brazil)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.format.extent699-710
dc.identifierhttp://dx.doi.org/10.1097/FTD.0000000000000222
dc.identifier.citationTherapeutic Drug Monitoring. Philadelphia: Lippincott Williams & Wilkins, v. 37, n. 6, p. 699-710, 2015.
dc.identifier.doi10.1097/FTD.0000000000000222
dc.identifier.issn0163-4356
dc.identifier.urihttp://hdl.handle.net/11449/164991
dc.identifier.wosWOS:000365594600002
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofTherapeutic Drug Monitoring
dc.relation.ispartofsjr0,656
dc.rights.accessRightsAcesso restritopt
dc.sourceWeb of Science
dc.subjectdaptomycin
dc.subjectcyclic lipopeptides
dc.subjectanalytical methods
dc.subjectresistant strains
dc.subjectantimicrobial
dc.titleDaptomycin: Physicochemical, Analytical, and Pharmacological Propertiesen
dc.typeResenhapt
dcterms.rightsHolderLippincott Williams & Wilkins
dspace.entity.typePublication
relation.isDepartmentOfPublicatione214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isDepartmentOfPublication.latestForDiscoverye214da1b-9929-4ae9-b8fd-655e9bfeda4b
unesp.author.orcid0000-0001-7253-2629[2]
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos